Performance of Three Tests for SARS-CoV-2 on a University Campus Estimated Jointly with Bayesian Latent Class Modeling.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
23 02 2022
Historique:
pubmed: 20 1 2022
medline: 22 3 2022
entrez: 19 1 2022
Statut: ppublish

Résumé

Accurate tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been critical in efforts to control its spread. The accuracy of tests for SARS-CoV-2 has been assessed numerous times, usually in reference to a gold standard diagnosis. One major disadvantage of that approach is the possibility of error due to inaccuracy of the gold standard, which is especially problematic for evaluating testing in a real-world surveillance context. We used an alternative approach known as Bayesian latent class modeling (BLCM), which circumvents the need to designate a gold standard by simultaneously estimating the accuracy of multiple tests. We applied this technique to a collection of 1,716 tests of three types applied to 853 individuals on a university campus during a 1-week period in October 2020. We found that reverse transcriptase PCR (RT-PCR) testing of saliva samples performed at a campus facility had higher sensitivity (median, 92.3%; 95% credible interval [CrI], 73.2 to 99.6%) than RT-PCR testing of nasal samples performed at a commercial facility (median, 85.9%; 95% CrI, 54.7 to 99.4%). The reverse was true for specificity, although the specificity of saliva testing was still very high (median, 99.3%; 95% CrI, 98.3 to 99.9%). An antigen test was less sensitive and specific than both of the RT-PCR tests, although the sample sizes with this test were small and the statistical uncertainty was high. These results suggest that RT-PCR testing of saliva samples at a campus facility can be an effective basis for surveillance screening to prevent SARS-CoV-2 transmission in a university setting.

Identifiants

pubmed: 35044220
doi: 10.1128/spectrum.01220-21
pmc: PMC8768831
doi:

Substances chimiques

Antigens, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0122021

Références

Lancet Child Adolesc Health. 2020 Nov;4(11):817-827
pubmed: 32758453
Clin Infect Dis. 2021 Nov 2;73(9):e3127-e3129
pubmed: 33570097
J Med Virol. 2020 Nov;92(11):2312-2313
pubmed: 32383182
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1642-1647
pubmed: 33382679
Elife. 2020 Feb 24;9:
pubmed: 32091395
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
PLoS One. 2021 Sep 2;16(9):e0249143
pubmed: 34473726
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200268
pubmed: 34053255
Stat Med. 1986 Jan-Feb;5(1):21-7
pubmed: 3961312
JAMA Health Forum. 2021 Oct 1;2(10):e213035
pubmed: 35977169
Nat Hum Behav. 2020 Sep;4(9):964-971
pubmed: 32759985
JAMA Netw Open. 2021 Jun 1;4(6):e2116425
pubmed: 34170303
Euro Surveill. 2020 Dec;25(50):
pubmed: 33334398
Nat Commun. 2021 Jan 7;12(1):356
pubmed: 33414470
N Engl J Med. 2020 Dec 17;383(25):2417-2426
pubmed: 33176077
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
BMJ. 2020 May 12;369:m1808
pubmed: 32398230
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32817233
Sci Rep. 2021 Feb 4;11(1):3134
pubmed: 33542443
JAMA Pediatr. 2021 Oct 1;175(10):e212025
pubmed: 34115094
PLoS Med. 2021 Sep 28;18(9):e1003777
pubmed: 34582457
J Med Virol. 2021 Feb;93(2):639-640
pubmed: 32770741
Lancet Infect Dis. 2020 Dec;20(12):1381-1389
pubmed: 32822577
JAMA Netw Open. 2020 Jul 1;3(7):e2016818
pubmed: 32735339
J Infect Dis. 2021 Sep 17;224(6):976-982
pubmed: 34191025
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
Epidemiol Infect. 2022 Jan 07;150:e21
pubmed: 35068403
Lancet Microbe. 2021 Jul;2(7):e311-e319
pubmed: 33846704
Am J Epidemiol. 2021 Aug 1;190(8):1689-1695
pubmed: 33823529
JAMA Intern Med. 2021 Jul 1;181(7):913-921
pubmed: 33821922
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
PLoS One. 2020 Dec 10;15(12):e0242958
pubmed: 33301459
JAMA Intern Med. 2021 Mar 1;181(3):353-360
pubmed: 33449069
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Lancet Reg Health Eur. 2021 Apr;3:100014
pubmed: 33871470
Lancet Infect Dis. 2021 Jul;21(7):929-938
pubmed: 33765417
J Clin Microbiol. 2021 Apr 20;59(5):
pubmed: 33504593
Sci Adv. 2021 Jan 1;7(1):
pubmed: 33219112
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447

Auteurs

T Alex Perkins (TA)

Department of Biological Sciences, University of Notre Damegrid.131063.6, Notre Dame, Indiana, USA.

Melissa Stephens (M)

Genomics and Bioinformatics Core Facility, University of Notre Damegrid.131063.6, Notre Dame, Indiana, USA.

Wendy Alvarez Barrios (W)

Notre Dame Research, University of Notre Damegrid.131063.6, Notre Dame, Indiana, USA.

Sean Cavany (S)

Department of Biological Sciences, University of Notre Damegrid.131063.6, Notre Dame, Indiana, USA.

Liz Rulli (L)

Notre Dame Research, University of Notre Damegrid.131063.6, Notre Dame, Indiana, USA.

Michael E Pfrender (ME)

Department of Biological Sciences, University of Notre Damegrid.131063.6, Notre Dame, Indiana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH